HROW NASDAQ
Harrow Health, Inc.
1W: +3.6%
1M: -8.0%
3M: -24.8%
YTD: -41.8%
1Y: -24.5%
3Y: +101.9%
5Y: +189.0%
$29.07
+0.12 (+0.41%)
Weekly Expected Move ±5.5%
$25
$27
$28
$30
$32
Credit Risk of going bust: higher than 70% of companies Debt: 21.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.96 (down 97%), Harrow Health, Inc. would be worth roughly what it owes.
Total debt $300.7M against a stock market value of $1.09B.
Distance to default 3.45 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $146.2M (short-term plus half of long-term), stock volatility 65.5%; Altman Z 1.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.96 (down 97%), Harrow Health, Inc. would be worth roughly what it owes.
Total debt $300.7M against a stock market value of $1.09B.
Distance to default 3.45 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $146.2M (short-term plus half of long-term), stock volatility 65.5%; Altman Z 1.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
39 relationships38
As Filer
counterparties named
1
As Counterparty
mentioned by others
4
Rel. Types
2021-04-08
Earliest Filing
2025-11-18
Latest Filing
partner: 20
target: 8
acquirer: 5
customer: 5
Counterparties (Filed by HROW)
38 relationshipsCompanies named in HROW's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Melt Pharmaceuticals, Inc. | — | target | Acquired by Harrow in a strategic expansion of its ophthalmic disease management portfolio. | 2025-11-18 | View |
| Harrow | HROW | acquirer | Leading provider of ophthalmic disease management solutions acquiring Melt Pharmaceuticals. | 2025-09-26 | View |
| Melt Pharmaceuticals | — | target | Clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation being acquired by Harrow. | 2025-09-26 | View |
| Novartis Technology, LLC | NVSEF | customer | Received a one-time milestone payment from Harrow, Inc. upon commercial availability of Triescence. | 2024-10-28 | View |
| Novartis Innovative Therapies AG | NVSEF | customer | Received a one-time milestone payment from Harrow, Inc. upon commercial availability of Triescence. | 2024-10-28 | View |
| Harrow Eye, LLC | HROW | partner | Counterparty to License Agreement effective July 10, 2023 | 2023-07-21 | View |
| Novaliq GMBH | — | partner | Counterparty to License Agreement effective July 10, 2023 | 2023-07-21 | View |
| Eyevance Pharmaceuticals, LLC | — | partner | Counterparty to Asset Purchase Agreement effective July 18, 2023 | 2023-07-21 | View |
| Santen S.A.S. | — | partner | Counterparty to License Agreement effective July 18, 2023 | 2023-07-21 | View |
| Harrow IP, LLC | HROW | partner | Counterparty to License Agreement effective July 10, 2023 | 2023-07-21 | View |
| U.S. Bank Trust Company, National Association | — | partner | Trustee for the Second Supplemental Indenture | 2022-12-20 | View |
| Harrow Health, Inc. | HROW | partner | Company issuing 11.875% Senior Notes due 2027 | 2022-12-20 | View |
| Novartis Ophthalmics AG | NVSEF | partner | Counterparty to the Asset Purchase Agreement for the Acquisition. | 2022-12-16 | View |
| Novartis Technology, LLC | NVSEF | partner | Counterparty to the Asset Purchase Agreement for the Acquisition. | 2022-12-16 | View |
| Novartis Innovative Therapies AG | NVSEF | target | Seller of assets including Product NDAs and intellectual property | 2022-12-14 | View |
| Harrow IP, LLC | HROW | acquirer | Purchaser of assets including Product NDAs and intellectual property | 2022-12-14 | View |
| Harrow Eye, LLC | HROW | acquirer | Purchaser of assets including Product NDAs and intellectual property | 2022-12-14 | View |
| Harrow Health, Inc. | HROW | acquirer | Purchaser of assets including Product NDAs and intellectual property | 2022-12-14 | View |
| Novartis Technology LLC | NVSEF | target | Seller of assets including Product NDAs and intellectual property | 2022-12-14 | View |
| Melt Pharmaceuticals, Inc. | — | customer | Borrower in a loan and security agreement amended to extend maturity and adjust liquidity requirements. | 2022-04-13 | View |
| Novartis | NVSEF | target | Sold U.S. commercial rights to four branded eye drops to Harrow Health. | 2021-12-20 | View |
| ImprimisRx | — | partner | Wholly owned subsidiary of Harrow Health responsible for selling and distributing the acquired products. | 2021-12-20 | View |
| ImprimisRx | — | partner | Ophthalmic-focused business assuming U.S. sales and marketing for DEXYCU | 2021-12-09 | View |
| Harrow Health | HROW | partner | Parent company of ImprimisRx announcing expanded commercial alliance | 2021-12-09 | View |
| EyePoint Pharmaceuticals | EYPT | partner | Pharmaceutical company expanding commercial alliance for DEXYCU | 2021-12-09 | View |
| Melt Pharmaceuticals, Inc. | — | customer | Borrower in the loan agreement | 2021-09-02 | View |
| Harrow Health, Inc. | HROW | acquirer | Acquired U.S. and Canadian commercial rights for drug candidate MAQ-100 | 2021-08-18 | View |
| Wakamoto Pharmaceutical Co., Ltd. | — | target | Granted U.S. and Canadian commercial rights for drug candidate MAQ-100 | 2021-08-18 | View |
| Sintetica | — | target | Sintetica, S.A. is the seller of marketing and supply rights for the ophthalmic drug candidate AMP-100 to Harrow Health. | 2021-07-27 | View |
| U.S. Bank National Association | — | partner | Serving as trustee under the Indenture governing the Senior Notes. | 2021-06-17 | View |
| Cede & Co. | — | partner | Acting as nominee of the Depository Trust Company for the registration of the Notes. | 2021-06-17 | View |
| Harrow Health, Inc. | HROW | partner | Company issuing Series B Cumulative Preferred Stock | 2021-05-05 | View |
| KMJ Corbin & Company LLP | — | partner | Independent registered public accounting firm | 2021-04-20 | View |
| Harrow Health, Inc. | HROW | partner | Company issuing 8.625% Senior Notes due 2026 | 2021-04-20 | View |
| U.S. Bank National Association | — | partner | Trustee for the Indenture | 2021-04-20 | View |
| Cede & Co. | — | partner | Nominee of DTC for note issuance | 2021-04-20 | View |
| Eton Pharmaceuticals, Inc. | ETON | target | Company issuing common stock in an underwriting agreement | 2021-04-08 | View |
| Harrow Health, Inc. | HROW | customer | Selling Stockholder selling shares to the underwriter | 2021-04-08 | View |
Mentioned As Counterparty
1 mentionsOther companies that named HROW in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-05 | Material Agreement; Acquisition/Disposition; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-09-04 | Officer/Director Change; Exhibits | View | |
| 2026-08-10 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-08-06 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-06-03 | Regulation FD; Exhibits | View | |
| 2026-05-11 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-27 | Material Agreement; Financial Obligation; Other Events; Exhibits | Agreement | View |
| 2026-03-24 | Other Events; Exhibits | View | |
| 2026-03-24 | Other Events; Exhibits | View | |
| 2026-03-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-03-02 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-02 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-11-18 | Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities; Other E | Acquisition | View |
| 2025-11-10 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-06 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-10-01 | Financial Statements and Exhibits | View | |
| 2025-09-29 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-09-26 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-09-26 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR